Comparing Ipilimumab vs Nivolumab
| Ipilimumab | Nivolumab |
|
|---|
| Ipilimumab | Nivolumab |
|
|---|---|---|
|
Prescription only
Prescribed for Melanoma - Metastatic, Renal Cell Carcinoma, Colorectal Cancer, Malignant Pleural Mesothelioma, Melanoma. Ipilimumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Related suggestions Colorectal Cancer
|
| More about Ipilimumab | More about Nivolumab | |
| Ratings & Reviews | ||
|
Ipilimumab has an average rating of 6.6 out of 10 from a total of 5 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 20% reported a negative effect. |
Nivolumab has an average rating of 5.9 out of 10 from a total of 142 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 39% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Ipilimumab side effects |
View all Nivolumab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Yervoy | Opdivo | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
352.8 hours |
640.8 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 660 drugs are known to interact with Ipilimumab:
|
A total of 594 drugs are known to interact with Nivolumab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
N/A |
December 22, 2014 |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Lumakras
Lumakras is used to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) or colorectal cancer ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Mektovi
Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.